Payment overview · 2025
General Payments
$1,103.01
41 reported records · 10 companies
Healthcare provider profile · identity verified
Renee Hernandez, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BRONX, NY · NPI 1427152750
Verified facts
What the public records show
CMS Open Payments records show Renee Hernandez, MD received $1,103.01 in general payments during 2025 across 41 reported records.
AstraZeneca Pharmaceuticals LP accounted for 29.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 315 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $324.79 | 29.4% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $228.91 | 20.8% | 8 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $195.67 | 17.7% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $155.50 | 14.1% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $76.16 | 6.9% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $30.92 | 2.8% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $30.10 | 2.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $25.97 | 2.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.07 | 1.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.92 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,103.01 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $228.91 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $208.13 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $198.56 | 7 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $195.67 | 7 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $195.67 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $155.50 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $155.50 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $116.66 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $52.23 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $52.23 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $41.89 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $30.92 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $30.10 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $23.93 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 131 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 112 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 217 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
131 | 39 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
61 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
112 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
152 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
217 | 43 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
315 | 69 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1022 | 303 |
| Omeprazole | Omeprazole | 628 | 201 |
| Metformin Hcl | Metformin Hcl | 590 | 180 |
| Azithromycin | Azithromycin | 586 | 293 |
| Metoprolol Succinate | Metoprolol Succinate | 432 | 129 |
| Amlodipine Besylate | Amlodipine Besylate | 400 | 134 |
| Lisinopril | Lisinopril | 381 | 106 |
| Eliquis | Apixaban | 315 | 69 |
| Gabapentin | Gabapentin | 310 | 94 |
| Prednisone | Prednisone | 288 | 170 |
| Fluticasone Propionate | Fluticasone Propionate | 282 | 73 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 270 | 83 |
| Celecoxib | Celecoxib | 248 | 87 |
| Simvastatin | Simvastatin | 243 | 73 |
| Furosemide | Furosemide | 239 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 238 | 67 |
| Ozempic | Semaglutide | 217 | 43 |
| Losartan Potassium | Losartan Potassium | 215 | 68 |
| Diclofenac Sodium | Diclofenac Sodium | 210 | 80 |
| Tamsulosin Hcl | Tamsulosin Hcl | 205 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 190 | 56 |
| Januvia | Sitagliptin Phosphate | 189 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 176 | 58 |
| Montelukast Sodium | Montelukast Sodium | 170 | 49 |
| Memantine Hcl | Memantine Hcl | 168 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 164 | 54 |
| Naproxen | Naproxen | 160 | 61 |
| Entresto | Sacubitril/Valsartan | 159 | 32 |
| Trulicity | Dulaglutide | 152 | 26 |
| Linzess | Linaclotide | 146 | 34 |
| Meclizine Hcl | Meclizine Hcl | 144 | 49 |
| Alendronate Sodium | Alendronate Sodium | 133 | 43 |
| Ezetimibe | Ezetimibe | 132 | 41 |
| Farxiga | Dapagliflozin Propanediol | 131 | 39 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 125 | 88 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 124 | 51 |
| Trazodone Hcl | Trazodone Hcl | 121 | 44 |
| Spironolactone | Spironolactone | 118 | 30 |
| Nifedipine Er | Nifedipine | 115 | 35 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 114 | 35 |
| Jardiance | Empagliflozin | 112 | 33 |
| Glimepiride | Glimepiride | 109 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 108 | 25 |
| Ibuprofen | Ibuprofen | 101 | 34 |
| Famotidine | Famotidine | 97 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 97 | 35 |
| Atenolol | Atenolol | 85 | 20 |
| Ketoconazole | Ketoconazole | 85 | 34 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 81 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 76 | 59 |
| Carvedilol | Carvedilol | 75 | 30 |
| Glipizide Er | Glipizide | 75 | 20 |
| Ammonium Lactate | Ammonium Lactate | 72 | 20 |
| Vascepa | Icosapent Ethyl | 72 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 68 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 24 |
| Donepezil Hcl | Donepezil Hcl | 67 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 66 | 17 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 62 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 61 | 25 |
| Vraylar | Cariprazine Hcl | 60 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 59 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 17 |
| Xarelto | Rivaroxaban | 59 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 40 |
| Finasteride | Finasteride | 57 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 22 |
| Nebivolol Hcl | Nebivolol Hcl | 55 | 15 |
| Glipizide | Glipizide | 53 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 53 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 52 | 14 |
| Meloxicam | Meloxicam | 52 | 21 |
| Memantine Hcl Er | Memantine Hcl | 45 | suppressed |
| Repatha Sureclick | Evolocumab | 45 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 42 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Clonazepam | Clonazepam | 41 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | 11 |
| Tramadol Hcl | Tramadol Hcl | 39 | 15 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 36 | 20 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 36 | 15 |
| Enalapril Maleate | Enalapril Maleate | 36 | suppressed |
| Clotrimazole | Clotrimazole | 35 | suppressed |
| Allopurinol | Allopurinol | 34 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 34 | 11 |
| Colchicine | Colchicine | 33 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Tradjenta | Linagliptin | 32 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | 12 |
| Potassium Chloride | Potassium Chloride | 31 | 15 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 29 | 16 |
| Methotrexate | Methotrexate Sodium | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Procto-Med Hc | Hydrocortisone | 28 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Belsomra | Suvorexant | 26 | suppressed |
| Erythromycin | Erythromycin Base | 26 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Clonidine | Clonidine | 25 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 25 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 25 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | suppressed |
| Folic Acid | Folic Acid | 22 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Famciclovir | Famciclovir | 21 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 19 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Restasis | Cyclosporine | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Kerendia | Finerenone | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Alprazolam | Alprazolam | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 15 | suppressed |
| Nexletol | Bempedoic Acid | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Leflunomide | Leflunomide | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | 13 |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,103.01 · 41 records | AstraZeneca Pharmaceuticals LP | BREZTRI, FANAPT, FARXIGA, HETLIOZ, IBSRELA, JARDIANCE, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, REPATHA, REXULTI, Rybelsus, VERQUVO, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error